Abeona Therapeutics’ (ABEO) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has a $18.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently commented on ABEO. StockNews.com raised Abeona Therapeutics from a sell rating to a hold rating in a report on Tuesday, September 10th. Stifel Nicolaus assumed coverage on Abeona Therapeutics in a research note on Thursday, May 30th. They issued a buy rating and a $21.00 price objective for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $15.00 target price on shares of Abeona Therapeutics in a research note on Wednesday, August 14th.

Abeona Therapeutics Price Performance

Shares of NASDAQ ABEO opened at $5.86 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.48 and a current ratio of 7.48. The firm has a fifty day moving average of $5.24 and a 200 day moving average of $5.40. The firm has a market cap of $240.04 million, a PE ratio of -1.83 and a beta of 1.53. Abeona Therapeutics has a one year low of $3.05 and a one year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.42). As a group, research analysts predict that Abeona Therapeutics will post -1.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

A number of large investors have recently made changes to their positions in ABEO. Jump Financial LLC purchased a new position in Abeona Therapeutics during the fourth quarter worth approximately $199,000. Acadian Asset Management LLC purchased a new position in shares of Abeona Therapeutics during the 1st quarter worth $91,000. Western Standard LLC raised its holdings in shares of Abeona Therapeutics by 68.5% during the 1st quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock worth $9,871,000 after acquiring an additional 553,377 shares during the period. Rosalind Advisors Inc. acquired a new position in shares of Abeona Therapeutics during the 2nd quarter valued at about $7,420,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after purchasing an additional 2,434 shares during the period. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.